Cypherpunk Technologies Inc.

NasdaqCM:CYPH 株式レポート

時価総額：US$106.0m

Cypherpunk Technologies 過去の業績

過去 基準チェック /06

Cypherpunk Technologiesの収益は年間平均-4.6%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間31.9% 83.3%割合で 減少しています。

主要情報

-4.58%

収益成長率

28.35%

EPS成長率

Biotechs 業界の成長17.04%
収益成長率-83.28%
株主資本利益率-67.45%
ネット・マージンn/a
前回の決算情報31 Mar 2026

最近の業績更新

Recent updates

分析記事 • Mar 13

Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
分析記事 • Nov 22

Will Leap Therapeutics (NASDAQ:LPTX) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 12

Leap Therapeutics GAAP EPS of -$0.15 misses by $0.05

Leap Therapeutics press release (NASDAQ:LPTX): Q2 GAAP EPS of -$0.15 misses by $0.05. Cash and cash equivalents totaled $90.9 million at June 30, 2022, expected to provide financial runway to mid-2024 Shares +1.54% PM.
Seeking Alpha • Jul 12

Leap Therapeutics begins trials of DKN-01 in gastric/colorectal cancers

Leap Therapeutics (NASDAQ:LPTX) said part C of an ongoing phase 2 trial of its medicine DKN-01, in combination with BeiGene (NASDAQ:BGNE) and Novartis' (NVS) tislelizumab, has begun in patients with gastric or gastroesophageal junction cancer (G/GEJ). The phase 2 trial, dubbed DisTinGuish will evaluate DKN-01 with tislelizumab and standard of care (SOC) chemotherapy in patients with inoperable, locally advanced, G/GEJ cancer. Part C will evaluate DKN-01 in combination with tislelizumab and SOC chemotherapy, compared to tislelizumab and SOC chemotherapy in ~160 first-line, HER2-negative patients who have had no prior therapy for unresectable locally advanced or metastatic G/GEJ cancer. In addition, Leap said it was starting a new trial of DKN-01 in combination with Roche's Avastin (bevacizumab) and chemotherapy in second-line patients with colorectal cancer. The company noted that it was also supporting an investigator-initiated trial of DKN-01 plus Merck's Keytruda (pembrolizumab) in patients with endometrial cancer, a type of cancer which begins in the uterus.
Seeking Alpha • Jun 27

Leap Therapeutics: 2 Catalysts With Cancer Drug DKN-01 In The 2nd Half Of 2022

Positive results using DKN-01 plus chemotherapy for the treatment of patients with metastatic castration-resistant prostate cancer were presented at ASCO 2022 medical conference. The global prostate cancer market could reach $12 billion by 2025. Positive initial results using DKN-01 in both 1st line and 2nd line DKK1-high expression gastric cancer patients were released, Updated data for both expected Q3 and Q4 of 2022 respectively. Leap Therapeutics had $103.2 million in cash as of March 31, 2022; It believes that it has enough to fund its operations for at least the next 12 months from the date of the SEC filing of May 13, 2022.
分析記事 • May 01

Here's Why We're Watching Leap Therapeutics' (NASDAQ:LPTX) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Feb 18

Leap Therapeutics: Waiting For One More Leap

I bought LPTX stock expecting a quick profit after a spike following data. The spike did happen, but I bought a little too high. I am expecting part B data to be strong enough for me to make a profit and exit.
分析記事 • Jan 04

We're Hopeful That Leap Therapeutics (NASDAQ:LPTX) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Nov 29

Leap Therapeutics: What Prompted Prioritizing This Precision Oncology Company?

Shares of this small oncology company have risen by 45% over the past three months, yet are down 10% over the past month. One goal for both myself and readers is to cultivate the ability to rapidly identify highly asymmetric setups - LPTX fits that description after ESMO data in gastric/GEJ patients. I delve into the results, conference calls and explain what I saw that led me to prioritize gaining exposure to this name (including optionality in other cancers). Devil's advocate is that majority of China economics (the largest market opportunity for gastric cancer) are locked up by BeiGene. Additionally, pulmonary embolism is an AE to look out for. LPTX is a Buy. Catalyst pipeline for 2022 includes ASCO GI data in January, final PFS data at ASCO in June and trial starts for additional indications.
Seeking Alpha • Oct 13

Leap Therapeutics: All On The Line

Leap Therapeutics is an early stage oncology company with a single active asset. Their single asset focuses on a pathway that is dysregulated in multiple cancers. Early data is a mixed bag, with potential efficacy seen in gastric cancer. Investing in Leap Therapeutics can be considered a high risk/high reward play.
分析記事 • Sep 15

Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
分析記事 • Jun 01

Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • Mar 03

Companies Like Leap Therapeutics (NASDAQ:LPTX) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...
分析記事 • Jan 27

Could The Leap Therapeutics, Inc. (NASDAQ:LPTX) Ownership Structure Tell Us Something Useful?

A look at the shareholders of Leap Therapeutics, Inc. ( NASDAQ:LPTX ) can tell us which group is most powerful...
分析記事 • Dec 23

Announcing: Leap Therapeutics (NASDAQ:LPTX) Stock Increased An Energizing 127% In The Last Year

Unfortunately, investing is risky - companies can and do go bankrupt. But if you pick the right stock, you can make a...
分析記事 • Nov 18

Need To Know: Analysts Are Much More Bullish On Leap Therapeutics, Inc. (NASDAQ:LPTX)

Leap Therapeutics, Inc. (NASDAQ:LPTX) shareholders will have a reason to smile today, with the analysts making...

収支内訳

Cypherpunk Technologies の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqCM:CYPH 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
31 Mar 260-571313
31 Dec 25051126
30 Sep 250-511038
30 Jun 250-661152
31 Mar 250-701259
31 Dec 240-681357
30 Sep 240-651356
30 Jun 240-601351
31 Mar 240-531445
31 Dec 230-811472
30 Sep 230-811471
30 Jun 230-821371
31 Mar 230-861374
31 Dec 220-551243
30 Sep 220-531241
30 Jun 221-491138
31 Mar 221-421132
31 Dec 212-411131
30 Sep 212-371028
30 Jun 212-321024
31 Mar 212-291022
31 Dec 202-381020
30 Sep 201-391021
30 Jun 201-40921
31 Mar 200-42922
31 Dec 190-33924
30 Sep 190-24926
30 Jun 190-22926
31 Mar 190-21924
31 Dec 180-23921
30 Sep 180-31918
30 Jun 180-31918
31 Mar 180-31818
31 Dec 170-301021
30 Sep 170-29821
30 Jun 170-30820
31 Mar 170-30722
31 Dec 160-26420
30 Sep 160-23419
30 Jun 160-19315
31 Mar 160-14212

質の高い収益: CYPHは現在利益が出ていません。

利益率の向上: CYPHは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: CYPHは利益が出ておらず、過去 5 年間で損失は年間4.6%の割合で増加しています。

成長の加速: CYPHの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: CYPHは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 43% ) と比較することは困難です。

株主資本利益率

高いROE: CYPHは現在利益が出ていないため、自己資本利益率 ( -67.45% ) はマイナスです。

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/18 10:16
終値2026/05/15 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Cypherpunk Technologies Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4

アナリスト機関
Swayampakula RamakanthH.C. Wainwright & Co.
Wangzhi LiLadenburg Thalmann & Company
Tyler Van BurenPiper Sandler Companies